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Public healtha b s t r a c t
Introduction: An unexpected resurgence of pertussis cases and infant deaths was observed in some coun-
tries that had switched to acellular pertussis vaccines in the primary immunisation schedule. In response
to the outbreaks, maternal pertussis vaccination programmes in pregnant women have been adopted
worldwide, including the USA in 2011 and the UK in 2012. Following the success of the programme in
England, we evaluated the health and economic impact of stopping versus continuing the maternal per-
tussis immunisation to inform public health policy making.
Methods: We used a mathematical model to estimate the number of infant hospitalisations and deaths
related to pertussis in England over 2019–2038. Losses in quality-adjusted life years, QALYs, were consid-
ered for infants (aged 0–2 months) who survived or died from pertussis, bereaved parents (of infants who
died from pertussis), and women with pertussis (aged 20–44 years). Direct medical costs to the National
Health Service included infant hospitalisations, maternal vaccinations, and disease in women. Costs and
QALYs were discounted at 3.5%. Changes in the incremental cost-effectiveness ratio, ICER, were explored
in sensitivity analyses.
Results: The model supports continuing the maternal pertussis immunisation programme as a cost-
effective intervention at an ICER of £14,500/QALY (2.5% and 97.5%-quantile: £7,300/QALY to £32,400/
QALY). Stopping versus continuing the maternal programme results in an estimated mean of 972 (range
582 to 1489) versus 308 (184 to 471) infant hospitalisations annually. Results were most sensitive to the
number of hospitalisations and deaths when stopping the maternal programme. At a cost-effectiveness
threshold of £30,000/QALY, the probability of the maternal programme being cost-effective was 96.2%.
Conclusion: Our findings support continuing the maternal pertussis vaccination programme as otherwise
higher levels of disease activity and infant mortality are expected to return. These results have led policy
makers to decide to continue the maternal programme in the UK routine immunisation schedule.
Crown Copyright  2021 Published by Elsevier Ltd.1. Introduction
The year 2012 saw a rise in pertussis (‘‘whooping cough”) case
numbers ten-fold higher than in previous years. This spike was
observed across all age groups in England with the highest case-
fatality rates among infants aged 0–2 months; a population tooyoung to be vaccinated and directly protected by primary immuni-
sation.[1]
The likely cause of this resurgence is thought to be the switch
from a whole cell pertussis (wP) vaccine to an acellular pertussis
(aP) vaccine in 2004.[2] Similar resurgences have been observed
in other countries who also switched to aP vaccines. These coun-
tries include the USA, Australia, and Portugal.[2,3] It is hypothe-
sised that aP vaccines result in a shorter duration of protection
against infection and disease compared to wP vaccines.[3]
F. Sandmann, M. Jit, N. Andrews et al. Vaccine 39 (2021) 4500–4509As an emergency outbreak response measure to the disease
resurgence, a pertussis vaccine has been offered to all pregnant
women in the UK since October 2012. Pregnant women are cur-
rently advised to receive one dose of a combination diphtheria/teta
nus/aP/inactivated polio (dTaP/IPV) vaccine in each pregnancy
from gestational week 16.[4] Maternal pertussis immunisation is
recommended by the World Health Organization (WHO) as a sup-
plementary strategy,[5] and it has been implemented in a number
of countries (including Australia, Belgium, Brazil, Mexico, Switzer-
land, and the USA).[4,6]
The maternal pertussis vaccination programme has been shown
to be safe and highly effective in protecting infants.[1,4,6–8] In
England, the maternal programme reduced the number of hospital-
isations and deaths among infants aged 0–2 months to similar (if
not lower) levels than those reported in 1998–2009.[9,10] This
was in sharp contrast to the epidemiology observed in all other
age groups, in which numbers of hospitalisations continued to rise
and levelled off at a newly established level.[1]
Due to the maternal programme being initially introduced in
response to the 2012 outbreak, the Joint Committee on Vaccination
and Immunisation (JCVI) convened to decide whether to incorpo-
rate it as a permanent part of the UK routine immunisation sched-
ule by 2019.[1] Given that such recommendations by JCVI require
evidence of cost-effectiveness,[11] the aim of our study is to inform
the review of whether it is cost-effective to make the maternal per-
tussis vaccination programme permanent after 2019. Our analysis
is framed in terms of stopping (de-funding) versus continuing the
maternal programme. This framing reflects the potential asymme-
try between equal-sized gains and losses due to loss aversion and
endowment effects, with dis-investment decisions of an existing
programme possibly requiring larger cost savings to compensate
for health losses than the amounts accepted for equivalent health
gains with investment decisions.[12–14]2. Methods
2.1. Design, setting and participants
We performed a cost-effectiveness analysis of the maternal per-
tussis vacation programme from the perspective of the National
Health Service (NHS) in England over 20 years (2019–2038). We
discounted future costs and quality-adjusted life years (QALYs) at
the recommended 3.5%.[11,15] For an overview of input parame-
ters see Table 1.
We focused on infants aged 0–2 months, who are the target
group of the maternal pertussis programme, as they are too young
to be vaccinated and directly protected by primary immunisation.
They are also the most affected by the pertussis-related hospitali-
sations and deaths.[7–9] We also looked at laboratory-confirmed
as well as non-confirmed (mild) disease in mothers, and at the
health-related quality of life impact of bereaved parents of infants
who died from pertussis.2.2. Intervention scenario: Stopping the maternal pertussis vaccination
For the baseline epidemiology of the intervention scenario of
stopping (de-funding) the maternal programme, we obtained the
outputs of a previously developed transmission-dynamic model
parameterised using age-stratified pertussis notification data from
England and Wales over nearly six continuous decades (1956–
2013).[2] The model was originally developed to investigate the
potential cause of the pertussis outbreak in England in 2012, and
it did not include the maternal programme yet. Hence, the model
allows us to predict the baseline epidemiology for the intervention
scenario when stopping the maternal programme, assuming a4501near-immediate return to higher disease levels in infants given
the lower degree and duration of protection from infection by
the aP vaccines.[2,3] The model also considered the decreasing
proportion of individuals protected by wP vaccines over time. We
then up-scaled the model output of predicted notifications to hos-
pitalisations given that the majority of pertussis cases in infants
aged 0–2 months in England are hospitalised (unlike the older
age groups),[9] and we expect that most notified cases would be
admitted to the hospital. For more details on our modelling
approach see Appendix, pages 2–4.
Independently, we also explored a conservative scenario with-
out the programme of a constant number of 500 hospitalised
infants annually. This scenario was informed by a published
post-implementation evaluation that estimated median/mean
numbers across six non-vaccination scenarios of 630/670 pertussis
cases in ages 0–2 months annually for the 4-year means in 2014–
2017 and a minimum of 465 pertussis cases in ages 0–2 months
based on the lowest scenario that extrapolated the hospitalisation
trend observed for pertussis in ages 3–11 months.[7]
For disease in mothers without the maternal programme, we
adopted a similar approach to Van Hoek et al. (2016).[10] Our esti-
mated 3,920 cases annually were derived from the incidence seen
in infants in the peak month of 2012 (in August 2012 with 43.3 per
100,000 population) and the female population aged 20–44 years
in England in 2017 (9,053,090).[16] We assumed 20.0% with non-
confirmed mild disease and 8.8% being laboratory-confirmed
moderate-to-severe disease.[10]
2.3. Comparator scenario: Continuing the maternal pertussis
vaccination
For the comparator scenario of continuing the maternal vacci-
nation programme, the number of infant hospitalisations was
derived from the estimated numbers of the intervention scenario
(when stopping the programme). The estimated numbers were
adjusted by the estimated vaccine effectiveness (VE) in infants
(0.91, 95%-CI: 0.88, 0.94)[1] and the vaccine coverage estimates
from the Clinical Practice Research Datalink (CPRD). CPRD is a rep-
resentative sentinel clinical dataset of general practitioner (GP)
registered patients in England (see Appendix, pages 2–4).[1] In
sensitivity analyses we used the estimates of the ImmForm data-
set, which is a routinely collected extraction of GP records in Eng-
land. However, ImmForm is likely to have been underestimating
vaccine coverage before a change in the data extraction occurred
in April 2016.[1]
For disease in mothers with the maternal programme, we
reduced the estimated numbers without vaccination by the esti-
mated VE in adolescents and adults (0.89, 95%-CI: 0.19, 0.99)[17]
and the vaccine coverage (similar to infants; see above). We
assumed the same proportions as without the programme to dis-
tinguish non-confirmed from laboratory-confirmed disease in
mothers.[10]
2.4. Outcomes
The main outcome was the incremental cost-effectiveness ratio
(ICER), i.e. the change in costs over the change in QALYs.[14] In
general, depending on how the research question is framed, the
ICER may represent the additional-costs-per-QALY-gained (here:
of continuing vs. stopping the maternal programme), or the cost-
savings-per-QALY-lost (of stopping vs. continuing the maternal
programme). Conventionally, ICERs with positive changes in costs
and QALYs need to be below the cost-effectiveness threshold of
e.g. £30,000/QALY gained to be considered cost-effective. However,
ICERs with negative changes in costs and QALYs need to be above
the threshold to be considered cost-effective (indicating the larger
Table 1





Annual number of hospitalisations of infants (aged 0–2
mo.), without maternal pertussis vaccination
972a (500;
1,619a)
n/a base: Choi et al.,[2] notifications uprated to hospitalisations (1:1.2).
min: conservative assumption.[7]
max: Choi et al.,[2] uprated (1:2.0; see comparison in Appendix)
Coverage of maternal pertussis vaccination 0.751b (0.723;
0.900)
Beta base: CPRD (2017).
min: ImmForm (2017).
max: assumption.
Vaccine effectiveness in infants 0.910 (0.880;
0.940)
Beta base: mean VE in infants.[1]
min/max: 95%-CI.[1]
Proportion of infant deaths (aged 0–2 mo.) annually,
without maternal pertussis vaccination
0.031 (0.017;
0.047)
Beta base: as observed in 2011–09/2012.[10]
min: as observed in 2002–2009.[9]
max: base + 50%.
Proportion of infant deaths (aged 0–2 mo.) annually,
with maternal pertussis vaccination
0.014 (0.007;
0.031)
Beta base: as observed in 2012–2017.[7]
min: base 50%.
max: as without the programme.[10]
QALY loss in (surviving) infants from disease 0.097 (0.089;
0.106)
Normal base: mean value as in adults.[19]
min/max: range.[19]
QALY loss in infants from premature death 25.61 (20.49;
30.74)
Normal base: estimated from ONS (National life tables: United Kingdom), EQ-
5D norms (Ara and Brazier, 2010), and discounted at 3.5%.[11,15]
min/max: base ± 20%.
QALY loss in parents from premature death of infant 3.70 (0.00;
7.41)
Log-Normal base: estimated from ONS (National life tables: United Kingdom, and
Birth characteristics in England and Wales), EQ-5D utility impact of
anxiety/depression (Dolan, 1997), and discounted at 3.5%.[11,15]
min: excluded.
max: base + 100%.
Annual number of maternities in England (informing




Normal base: mean of 2012–2017 (Office for National Statistics, Birth
characteristics in England and Wales).
min/max: range of 2012–2017 (Office for National Statistics, Birth
characteristics in England and Wales).
Vaccine price per dose £20.00
(£12.00;
£22.74)
n/a (Fixed) base: British National Formulary, list price (tariff) in 2019.
min/max: British National Formulary, indicative list price in 2012/
2019.
Vaccine administration costs £10.06 (£7.67;
£15.00)
n/a (Fixed) base: NHS England, Enhanced service specifications (2019).
min: NHS England, Enhanced service specifications (2012).
max: base + 50%.








base: estimated from HES (2006–2011), PICANet (2006–09/2012), and
NHS Reference costs (2017–2018).
min/max: base ± 20%.








base: estimated from HES (2013–2017), PICANet (10/2012–2017),
and NHS Reference costs (2017–2018).
min/max: base ± 20%.
Illness in mothers (exploratory, largely following Van Hoek et al. [10])
Annual number of cases in women (aged 20–44 years),
without maternal pertussis vaccination
3,920 n/a (Fixed) base: estimated from infant pertussis incidence (2012)[10] and the
female population aged 20–44 years.[16]
scenario analyses: excluded.
Vaccine effectiveness in mothers 0.890 n/a (Fixed) base: VE in adults.[17]
scenario analyses: excluded.
Laboratory-confirmed disease in mothers 0.088 n/a (Fixed) base: based on Van Hoek et al.[10]
scenario analyses: excluded.
Non-confirmed mild disease in mothers 0.200 n/a (Fixed) base: based on Van Hoek et al.[10]
scenario analyses: excluded.
QALY loss of non-confirmed mild disease in mothers 0.036 n/a (Fixed) base: QALY loss of adults.[19]
scenario analyses: excluded.
QALY loss of laboratory-confirmed disease in mothers 0.097 n/a (Fixed) base: QALY loss of adults.[19]
scenario analyses: excluded.
Costs of non-confirmed mild disease in mothers £27.89 n/a (Fixed) base: costs of adults,[19] inflated to 2017.
scenario analyses: excluded.
Costs of laboratory-confirmed disease in mothers £60.44 n/a (Fixed) base: costs of adults,[19] inflated to 2017.
scenario analyses: excluded.
Methodological parameters
start year of the analysis 2019 (2012;
2024)
n/a (Fixed) base: status quo.
min: start year of the programme.[1]
max: base + 5 years.






stop year of the analysis 2038 (2028;
2048)
n/a (Fixed) base: 20 years to capture variation.[2]
min: 10 years short-term impact.max: 30 years to avoid method-
ological issues afterwards (HM Treasury, The Green book, 2018).
discount rate for costs and QALYs 0.035 (0.015;
0.05)
n/a (Fixed) base: NICE, JCVI.[11,15]
min: NICE, JCVI.[11,15]
max: exploratory.
CI: confidence interval, CPRD: Clinical Practice Research Datalink, EQ-5D: EuroQol Five Dimension, HES: hospital episode statistics, JCVI: Joint Committee on Vaccination and
Immunisation, NHS: National Health Service, NICE: National Institute for Health and Care Excellence, NOIDS: notifications of infectious diseases, PICANet: Paediatric Intensive
Care Audit Network, QALYs: quality-adjusted life years, VE: vaccine effectiveness.
a : Mean value of all scenarios and over 20 years shown here only for illustration (see main text).
b : For the sensitivity analysis exploring an earlier start year (2012, when the programme was introduced), we used the annualised coverage data in 2012–2017.
F. Sandmann, M. Jit, N. Andrews et al. Vaccine 39 (2021) 4500–4509cost savings needed to compensate for health losses becoming
acceptable).[14]
In this analysis, the pertussis-related QALY losses were based on
the estimated number of hospitalisations in infants and disease in
mothers (as outlined above) as well as infant mortality. The num-
ber of infant deaths was estimated using previously reported case-
fatality risks (CFRs) for hospitalised infants aged 0–2 months in
England. When stopping the programme we assumed the CFR to
return to levels seen in the 12 months preceding the maternal vac-
cination introduction (i.e., 10/2011–09/2012; 16/513 = 0.0312).
[10] With a continued programme we assumed the CFR to stay
at levels seen since the maternal vaccination introduction (i.e.,
10/2012–12/2017; 17/1,211 = 0.0140).[7] Our assumption that
when stopping the programme the infant CFR would return to
levels seen in the 12 months preceding the maternal vaccination
introduction is informed by (i) the continued and exclusive use
of aP vaccines in England since 2004,[1,2] (ii) the slightly higher
VE against death than against disease,[1] (iii) VE being highest in
the very youngest age groups (0 months) who may experience
the highest CFR,[1] and (iv) the CFRs reported in other settings
for the periods without a maternal vaccination programme (e.g.
4.7% in infants aged 0–2 months in Brazil).[18] Note that the share
of the population benefitting from having been primed (and
boosted) by wP vaccines also has been continuously decreasing,
and is lower compared to at the time of the outbreak in 2012.
We accounted for this in the transmission-dynamic model. In the
sensitivity analysis, when stopping the programme we also consid-
ered the return of the CFR to pre-2012 levels (i.e., in 2002–2009;
29/1,695 = 0.0171).[9]
The overall QALY loss due to pertussis was informed by esti-
mates for the QALY impact of illness episodes in surviving infants
and mothers from previously published studies in England and
Wales.[10,19] We estimated the QALY loss in infants from prema-
ture mortality due to pertussis using official statistics and the pop-
ulation norms in England (Appendix, page 5). We also quantified
the QALY loss in parents from premature infant mortality due to
pertussis to capture the emotional distress from losing a child.
[20] We assumed a severe impact on bereaved parents in terms of
‘‘anxiety/depression” in the first year and a moderate impact in
all subsequent years over the remaining life expectancy of parents.
We quantified the health loss using utility decrements and official
statistics for England. Additional caregiver QALY losses (e.g. in par-
ents) due to non-fatal infant cases have not been included. More
details on the QALY estimation can be found in Appendix, page 5.2.5. Costs
We estimated the costs of infant hospitalisations, the maternal
vaccination programme, and disease in mothers.4503For the costs of infant hospitalisations, we accounted for day
cases, overnight stays, and infants admitted to a paediatric inten-
sive care unit (PICU). In addition, infants admitted to the PICU
may require specialist transportation (retrieval), and extracorpo-
real membrane oxygenation (ECMO). The underlying data on pro-
portions and the lengths of stay were obtained for 2006–2017
from hospital episode statistics (HES) and the Paediatric Intensive
Care Audit Network (PICANet). We used NHS reference costs for
2017/2018. A full list of the corresponding cost and diagnostic
codes is listed in Appendix, pages 6–8.
For the costs of vaccination, we estimated the annual number of
vaccine doses based on the coverage estimates of CPRD[1] and the
annual number of officially recorded maternities in England. We
also used the coverage estimates of ImmForm in the sensitivity
analysis. We then used the NHS item-of-service payment to immu-
nisation providers and the official list price of the pertussis vacci-
nes, which is likely to be higher than the commercially-sensitive
price at which the vaccines are available as part of the national ten-
der (although the exact prices are unpublished and unknown to the
public). Therefore, we further varied the vaccine price in a separate
threshold analysis.
For the costs of disease in mothers, we considered the estimated
costs of laboratory-confirmed and non-confirmed (mild) disease in
adults in England (inflated to 2017).[19]2.6. Uncertainty analyses
Two deterministic sensitivity analyses explored the parameter
uncertainty by changing individual parameters in isolation. In the
first deterministic sensitivity analysis, we used the range of plausi-
ble values listed in Table 1 based on the individual uncertainty of
parameter estimates. In the second deterministic sensitivity analy-
sis, we changed sensible parameters uniformly by ± 35% (simply
chosen to reflect the 35% higher incidence scenario in Van Hoek
et al.).[10] Results were plotted in tornado plots, which rank the
parameters according to their highest-to-lowest impact on the
ICER.
In probabilistic sensitivity analysis we then explored the com-
bined uncertainty of parameters, using the distributions listed in
Table 1. We used 2,000 samples to report the 95% uncertainty
interval (95%-UI, i.e. 2.5%- and 97.5%-quantiles). We ran the prob-
abilistic analysis for both the base-case scenarios and the conserva-
tive minimum scenario.[7] We aimed to facilitate interpreting
results by plotting in a cost-effectiveness plane the original
research question (of stopping vs. continuing the programme)
and also its reverse format (of continuing vs. stopping).[14]
We also plotted the probability of interventions being cost-
effective for a range of willingness-to-pay thresholds
(£0-£50,000/QALY). We identified the optimal intervention based
F. Sandmann, M. Jit, N. Andrews et al. Vaccine 39 (2021) 4500–4509on the highest mean net benefit (under an assumed policy objec-
tive for the NHS of maximising health outcomes with limited
resources).[21] Lastly, we quantified the probabilities of being
cost-effective of different vaccine prices at £30,000/QALY.[11,15]
2.7. Software
The original transmission-dynamic model was coded in
MATLAB. The cost-effectiveness analysis was coded in R.
3. Results
Our model estimated a mean of 972 (median: 988; range 582 to
1489) versus 308 (313; 184 to 471) annual infant hospitalisations
when stopping the maternal programme versus continuing it
between 2019 and 2038 (Fig. 1). The annual number of deaths pre-
dicted in infants aged 0–2 months is an estimated mean of 4.3 (1.3,
9.5) deaths and 30.3 (95%-UI: 15.1, 50.7) deaths with and without
the programme, respectively. When comparing the predicted inci-
dence of notifications for the baseline intervention scenario with-
out maternal vaccination over time to the observed incidence the
predictions in the 0–2-month age group poorly matched the
observed notifications. This is to be expected as the predictions
do not account for the maternal pertussis vaccination programme
(Fig. 1A). In contract, the predictions in the 3–11-month age group
reasonably matched the observed notifications as they are only
marginally impacted by the maternal programme that aims to pro-
tect infants aged 0–2 months (Fig. 1B). Similarly, our estimated
hospitalisations in infants aged 0–2 months also matched the
observed number of hospitalisations, both for the period beforeFig. 1. Comparison of observed pertussis notifications (2010–2017) and predicted notific
and comparison of observed pertussis hospitalisations (2010–2017) and estimated ho
vaccination programme and d) with the maternal vaccination programme.
4504the introduction of the maternal vaccination programme (Fig. 1C)
and the period afterwards (Fig. 1D).
For an overview of the deterministic cost-effectiveness of stop-
ping the maternal pertussis vaccination in England in 2019–2038
(compared to continuing the programme) see Table 2. The annual
discounted costs of the programme for the NHS are estimated to be
a mean of £11.9 million (95%-UI: £10.2 million, £13.9 million) ver-
sus mean costs without the programme of £2.7 million (95%-UI:
£1.1 million, £6.3 million). The cost savings from stopping the pro-
gramme largely reflect avoided vaccinations, but at increased costs
of infant hospitalisations (Fig. 2A). The estimated annual QALY loss
without the programme resulted in a mean of 765 QALYs (95%-UI:
421, 1219) vs. a loss of 130 QALYs (59, 249) with the programme;
Fig. 2B). At incremental net cost savings of £9.2 million and incre-
mental health losses of 635 QALYs, stopping the programme is
expected to result in cost savings-per-QALY-lost of £14,500/QALY
(95%-UI: £7,300/QALY, £32,400/QALY). This is below the incremen-
tal cost-effectiveness threshold of £30,000 (and even £20,000) per
QALY lost; Fig. 2C. Stopping the programme is thus not cost-
effective as the cost savings are not large enough to offset the
health loss in terms of QALYs. The worst case explored in the con-
servative minimum scenario (i.e., n = 500) resulted in £29,400/
QALY (£19,000/QALY, £52,600/QALY); Fig. 2C. Overall, the incre-
mental costs per QALY favour continuing the programme.
Deterministic sensitivity analysis showed that the most sensi-
tive parameters were the number of hospitalisations and deaths
when stopping the programme (Fig. 3, and Appendix, page 9).
Probabilistic sensitivity analysis revealed that continuing the pro-
gramme with an assumed vaccine price of £20/dose had the high-
est probability of being cost-effective at a cost-effectivenessations (2010–2037) in a) infants aged 0–2 months and b) infants aged 3–11 months;
spitalisations (2010–2037) in infants aged 0–2 months c) without the maternal
Table 2
Deterministic cost-effectiveness results of stopping vs continuing the maternal pertussis vaccination in England, 2019–2038.
Outcomes Base-case analysis based on transmission-dynamic model
predictions.















Vaccine price (at £20/dose) 0 145,000,000 145,000,000 0 145,000,000 145,000,000
Vaccine administration 0 73,100,000 73,100,000 0 73,100,000 73,100,000
Medical costs (infants aged 0–2 months) 53,800,000 19,300,000 34,500,000 27,600,000 9,900,000 17,700,000
Medical costs (women aged 20–44 years) 628,000 208,000 420,000 628,000 208,000 420,000
Total costs (discounted at 3.5%) 54,400,000 238,000,000 184,000,000 28,300,000 229,000,000 200,000,000
Total costs (discounted at 1.5%) 64,400,000 282,000,000 218,000,000 33,500,000 271,000,000 237,000,000
Total costs (undiscounted) 73,900,000 323,600,000 250,000,000 38,400,000 311,000,000 272,000,000
QALY losses
Hospitalised infants with pertussis
(aged 0–2 months)
1,400 440 950 710 230 490
Infant deaths due to pertussis
(QALY loss in infants)
11,300 1,620 9,720 5,800 830 5,000
Infant deaths due to pertussis
(QALY loss in parents)
1,650 240 1,420 850 120 730
Women with pertussis (aged 20–
44 years)
910 300 610 910 300 610
Total QALY loss (discounted at 3.5%) 15,300 2,600 12,700 8,300 1,500 6,800
Total QALY loss (discounted at 1.5%) 28,000 4,490 –23,500 14,900 2,500 12,500
Total QALY loss (undiscounted) 51,000 7,840 43,200 26,900 4,200 –22,600
Incremental costs (in £) per 1 QALY
change
ICER (discounted at 3.5%) n/a n/a 14,500 n/a n/a 29,400
ICER (discounted at 1.5%) n/a n/a 9,200 n/a n/a 19,000
ICER (undiscounted) n/a n/a 5,800 n/a n/a 12,000
ICER: incremental cost-effectiveness ratio, n/a: not applicable, QALY: quality-adjusted life year.
The base-case analysis is more robust than the conservative scenario as it is based on a transmission-dynamic model exploring a wide range of plausible scenarios (Choi et al.,
2016), while the conservative scenario is based on an assumed constant number of 500 infant hospitalisations annually.
Unless stated otherwise, costs and QALYs discounted at 3.5%.[11,15] Due to rounding, values may not always add up precisely.
F. Sandmann, M. Jit, N. Andrews et al. Vaccine 39 (2021) 4500–4509threshold of £30,000/QALY (96.2%). The conservative minimum
scenario (of n = 500) had a probability of being cost-effective of
48.9% at £30,000/QALY and a vaccine price of £20/dose (Fig. 4),
which reached 90% at a vaccine price between £11-£12/dose (ex-
cluding administration costs; Appendix, page 10).4. Discussion
This study analysed the cost-effectiveness of stopping the exist-
ing emergency maternal pertussis vaccination versus adopting the
maternal vaccination programme as a permanent part of the
national immunisation schedule. Our findings suggest that stop-
ping the maternal programme would result in financial savings
for the NHS (largely by avoiding expenditures on vaccinations),
but would also result in increased expenditure on hospitalisations
as well as elevated health losses from infant mortality and morbid-
ity. Overall, the incremental costs per QALY favour continuing the
routine maternal vaccination programme (£14,500/QALY), i.e.
stopping the programme is unlikely to be considered cost-
effective.[11,15] Based on this study and additional evidence, the
JCVI recommended to continue emergency maternal immunisation
as a routine programme in the UK.[22]
Our findings are in line with previous economic evaluations of
maternal immunisation strategies internationally.[7,10,23,24]
Similar to previous studies,[24] our results are most sensitive to
the number of hospitalisations and deaths without the maternal
programme. However, the actual ICER is likely to be lower than
that presented here (i.e., even more favourable of continuing the
programme) given that we used published list prices for the vacci-
nes that are likely to be higher than the confidential, unpublished
tender prices actually paid by the NHS.4505In the future, infant cases in England may rise further due to the
increasing proportion of females primed with aP vaccines since
2004 that are reaching childbearing age. The impact of the boosting
effect in mothers primed by aP vaccines is still unclear. However,
more rapid waning of vaccine-induced protection in aP primed
children may also make them susceptible to natural infection
again, with longer lasting natural immunity that may reach well
into childbearing age.[2] Moreover, natural infection may also
become associated with substantial morbidity and mortality. Com-
bined with new vaccines being developed that may confer higher
degrees of indirect protection again,[25] the maternal pertussis
immunisation may need to be re-evaluated in the future.
There are additional reasons for continuing the programme
beyond cost-effectiveness considerations, such as the duty of care
towards vulnerable populations who are difficult to otherwise pro-
tect (such as infants too young to be directly protected via primary
immunisation).[8,26] We were also unable to quantify the broader
(societal) implications for the reputation and future coverage of the
pertussis vaccines if the programme was to be de-funded,[3] such
as the possible confusion this may cause about the benefit of per-
tussis vaccination. The maternal pertussis vaccine being publicly
funded was one of the key factors for women to accept the vaccine
during pregnancy in New Zealand.[27] Furthermore, the disruption
caused by a discontinued programme (even if only intermittently)
on the inter-epidemic cycle of pertussis is unclear, possibly leading
to long-run lower levels of uptake and making the pertussis infec-
tion prevention and control even more difficult than they have
already proven to be.[1,3,8] Including such considerations into
the appraisal of the maternal pertussis vaccination programme
should further support its continuation for as long as indirect pro-
tection against infection from the infant programme is insuffi-
ciently high.
Fig. 2. Results (mean, 2.5%- and 97.5%-quantile) of stopping vs. continuing the maternal pertussis vaccination programme in England for the base-case analysis and the
conservative scenario: Total costs (panel a); total QALY loss (panel b); and incremental costs-per-QALY (panel c, with unfavourable cost-effectiveness ratios >£30,000/QALY
shaded in grey).
F. Sandmann, M. Jit, N. Andrews et al. Vaccine 39 (2021) 4500–45095. Strengths and limitations
The study presented here is the first to explore the heath-
economic consequences of stopping thematernal pertussis vaccina-
tion programme in England after 2019. It also formed a part of the
body of evidence considered by the JCVI that led it to recommend
making the maternal pertussis vaccination programme permanent
in the UK routine immunisation schedule.[22] Despite framing the
analysis as exploring the potential disinvestment decision of stop-
ping (de-funding) versus continuing the routine maternal vaccina-
tion programme, we applied the same rules andmethods that apply
to investment decisions when introducing new interventions.
[11,15]Wealsoperformedrigoroussensitivityandscenarioanalyses
to address the various challenges and uncertainties encountered.
However, thenationaldatasets included inour analysisdidnot allow
for addressing socio-economic gradients for disease risk and cover-
age, despite the adjusted coverage for the maternal programme4506having been an estimated 14% lower in the most deprived group in
2014–2015.[28]
Furthermore, we assumed that stopping the programme would
result in a near-immediate return to higher disease levels in infants
given the lower degree and duration of protection from infection
afforded by the aP vaccines.[2,3] This also reflects the rapid
decrease in maternal antibody titres after delivery, hence the rec-
ommendation for mothers to receive the vaccine in each preg-
nancy.[8] The World Health Organization has cautioned against
switching to aP vaccines in countries that have not switched yet,
following outbreaks that occurred in four countries that exclu-
sively used aP vaccines and modelling studies suggested an
increased risk of death in infants too young to be vaccinated.[5]
In the future, we plan to use a dynamic model to analyse the resid-
ual immunity in vaccinated mothers for subsequent pregnancies,
as well as the residual indirect protection of the maternal pro-
gramme for the wider population. Moreover, in response to the
Fig. 3. Results of the deterministic sensitivity analysis (tornado plot), exploring a plausible range of values.
Fig. 4. Probability of being cost-effective at an assumed vaccine price of £20/dose (excluding administration costs) across thresholds of £0-£50,000/QALY in the base-case
analysis (a-b) and the conservative minimum scenario (c-d), and of interventions being optimal in achieving the highest mean net benefit (b, d). Note: The conservative
scenario is not equally likely to the scenarios underlying the base case analysis.
F. Sandmann, M. Jit, N. Andrews et al. Vaccine 39 (2021) 4500–4509coronavirus disease 2019 (COVID-19) pandemic, many countries
have adopted physical distancing measures, which impact cover-
age of routine childhood immunisation programmes as well as
reduce the transmission of other infectious diseases such as per-
tussis. The potential impact for the maternal pertussis programme
and the benefits of reduced transmission of pertussis will need to
be considered in the future.
Our conservative minimum scenario was independently
informed by a previously published post-implementation evalua-
tion to illustrate the possible impact in the extreme worst case4507of a constant number of 500 hospitalised infants annually even
without the programme.[7] Such an assumption is not necessar-
ily reflecting the most plausible scenario or of equal likelihood to
the best-fitting scenarios informing our base case. Moreover,
assuming a constant number of 500 infant hospitalisations annu-
ally without the programme equates to an expected 158 hospi-
talisations with the programme (at an uptake of 0.751 and
vaccine effectiveness of 0.910). This number is 24% lower than
the mean 207 infant inpatients actually observed between
2013 and 2017.[7]
F. Sandmann, M. Jit, N. Andrews et al. Vaccine 39 (2021) 4500–4509We also focused on the most important cost factors from the
healthcare provider perspective, and all major QALY losses. Studies
measuring the QALY loss in parents due to illness in their children
are rare and mostly focus on non-fatal illness episodes, e.g. in
parents of children with an illness episode of
rotavirus-associated gastroenteritis.[29] Studies measuring QALY
losses experienced by bereaved parents due to the premature
death of their child are even rarer, although the emotional distress
caused by infant deaths is well established.[20] By assuming a util-
ity decrement for bereaved parents on solely the dimension
‘‘anxiety/depression” of the EQ-5D, we ignored any possible impact
on other dimensions of quality of life as well as the impact on
others (e.g. grandparents, siblings, hospital staff). We also did not
account for any long-term disability in PICU survivors,[30] and
our sensitivity analysis revealed a larger impact of the discount
rate on QALYs than on costs. Therefore, we believe we have under-
estimated the magnitude of the cost-effectiveness of continuing
the routine maternal programme. Had we considered any of the
mentioned additional QALY losses prevented by the maternal pro-
gramme the net effect would likely be to make it more cost-
effective to continue.
In conclusion, our findings support continuing the maternal
pertussis vaccination programme in England as a cost-effective
strategy from the NHS perspective. The programme may need to
be re-evaluated once new vaccines offering sufficiently high indi-
rect protection become available.Funding sources
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